Skip to content
20-F

Annual Report (Foreign)

SOFGEN PHARMA, S.A.

0001213900-26-028293

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Dec 31, 2024 100.27K sh
Shares Diluted FY 2024 · Dec 31, 2023 101.01K sh
Shares Diluted FY 2024 · Dec 31, 2022 101.11K sh
Operating Cash Flow FY 2024 · Dec 31, 2024 $88.43M
Operating Cash Flow FY 2024 · Dec 31, 2023 $107.64M
Operating Cash Flow restated FY 2024 · Dec 31, 2022 $15.55M
Cash And Equivalents FY 2024 · Dec 31, 2024 $30.32M
Cash And Equivalents FY 2024 · Dec 31, 2023 $17.51M
Cash And Equivalents FY 2024 · Dec 31, 2022 $43M
Stockholders Equity FY 2024 · Dec 31, 2024 −$52.09M
Stockholders Equity FY 2024 · Dec 31, 2023 −$736K
Stockholders Equity restated FY 2024 · Dec 31, 2022 −$37.13M
Current Liabilities FY 2024 · Dec 31, 2024 $415.92M
Current Liabilities restated FY 2024 · Dec 31, 2023 $433.57M
Current Assets FY 2024 · Dec 31, 2024 $216.75M
Current Assets FY 2024 · Dec 31, 2023 $275.65M
Total Assets FY 2024 · Dec 31, 2024 $411.69M
Total Assets FY 2024 · Dec 31, 2023 $472.5M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.68
Eps Diluted FY 2024 · Dec 31, 2023 $0.40
Eps Diluted restated FY 2024 · Dec 31, 2022 $0.36
Eps Basic FY 2024 · Dec 31, 2024 −$0.68
Eps Basic FY 2024 · Dec 31, 2023 $0.40
Eps Basic restated FY 2024 · Dec 31, 2022 $0.36
Net Income FY 2024 · Dec 31, 2024 −$68.3M
Net Income FY 2024 · Dec 31, 2023 $40.34M
Net Income restated FY 2024 · Dec 31, 2022 $36.13M
Operating Income FY 2024 · Dec 31, 2024 −$53.99M
Operating Income FY 2024 · Dec 31, 2023 $72.08M
Operating Income FY 2024 · Dec 31, 2022 $9.81M
Gross Profit FY 2024 · Dec 31, 2024 $191.48M
Gross Profit FY 2024 · Dec 31, 2023 $237.98M
Gross Profit restated FY 2024 · Dec 31, 2022 $235.13M
Cost Of Revenue FY 2024 · Dec 31, 2024 $182.32M
Cost Of Revenue FY 2024 · Dec 31, 2023 $185.77M
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $168.08M
Revenue FY 2024 · Dec 31, 2024 $373.8M
Revenue FY 2024 · Dec 31, 2023 $423.75M
Revenue restated FY 2024 · Dec 31, 2022 $403.2M